Delpha Capital Management’s Biogen BIIB Stock Holding History

Delpha Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-70	Closed	-$22K	–	244
2017 Q4	$22K	Buy	+70	New	+$22.5K	0.02%	720

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Delpha Capital Management's BIIB Position: Q1 2018 in Review

Delpha Capital Management sold out of Biogen (BIIB) in Q1 2018, closing a stake of 70 shares — an estimated $22K sold.

Delpha Capital Management first reported a position in BIIB in Q4 2017 and held it in 1 quarter. The position peaked at $22K in Q4 2017. 1,102 funds tracked by Wall St. Rank hold BIIB as of Q1 2018.

Delpha Capital Management reported no remaining Biogen position as of Q1 2018 after selling out during the quarter.
Delpha Capital Management sold 70 Biogen shares in Q1 2018, an estimated $22K.
Delpha Capital Management first reported a position in Biogen in Q4 2017 and held it in 1 quarter.
Delpha Capital Management's Biogen position peaked at $22K in Q4 2017.
1,102 funds tracked by Wall St. Rank held Biogen as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.